【 摘 要 】
Prior to the availability of epoprostenol, lung transplantation was indicated when mean right atrial pressure was >15 mm Hg, mean pulmonary artery pressure was >55 mm Hg, and cardiac index was <2 L/mim/m2 and early survival was good. Subsequent to the availability of medical therapy, the indications for transplant have not changed but the patients are significantly more debilitated. Today, patients with PH have a significant early hazard with a 30-day survival of only 84% while patients with cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) have a survival of 95% and 95%, respectively.50 Based on a conditional survival of 3 months, there is no difference between PH, CF, and COPD each with a 6-month survival of 96%.50 This high early mortality seen after lung transplantation in patients with PH likely reflects the ability of vasodilator therapy to prolong life despite significant pathophysiology. Despite these sobering results, outcomes have improved since its original description and things must be kept in perspective.
【 授权许可】
All Rights reserved
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO201902199904275ZK.pdf | 95KB | download |